Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IDT Biologika

- PMLiVE

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition

- PMLiVE

Roche’s Actemra approved for severe COVID-19 in Europe

The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia

- PMLiVE

Mix-and-match COVID-19 vaccines may be more effective

A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

- PMLiVE

AstraZeneca blocks take-private buyout of Sobi

The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed

- PMLiVE

Lilly’s combination antibody expanded to children under 12

The FDA has expanded the emergency use for bamlanivimab with etesevimab for the treatment of and post-exposure prophylaxis against COVID-19 in high-risk children aged under 12

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

- PMLiVE

Annual COVID-19 jabs likely, says Pfizer head

Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children

- PMLiVE

Booster plans expanded to combat Omicron

As booster jab campaigns against COVID-19 are expanded in many countries, data from Israel backs up the benefits of being boosted

- PMLiVE

US regulators set to approve oral antiviral against COVID-19

The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next

- PMLiVE

COVID-19 vaccines against Omicron may be fast-tracked

Regulators including the Food and Drug Administration (FDA) may treat Omicron-specific mRNA vaccines like seasonal flu vaccines, speeding up approval

- PMLiVE

Omicron prompts global action

A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action

- PMLiVE

New COVID variant causing concern

An ‘unusual constellation of mutations’ in a new variant of the virus that causes COVID-19 has scientists worried that it could impact the efficacy of vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links